(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) fell by a staggering 31.26% in 21 sessions from $11.23 at 2023-02-01, to $7.72 at 12:45 EST on Friday, following the last session’s upward trend. NASDAQ is rising 1.35% to $11,618.25, following the last session’s upward trend.
Novavax’s last close was $6.93, 92.38% below its 52-week high of $91.00.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Yearly Top and Bottom Value
Novavax’s stock is valued at $7.72 at 12:45 EST, way under its 52-week low of $8.64.
Volatility
Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 8.91%, a negative 3.58%, and a positive 5.19%.
Novavax’s highest amplitude of average volatility was 12.31% (last week), 4.95% (last month), and 5.19% (last quarter).
More news about Novavax (NVAX).
